Form 4: UTHR COO Sells Shares Under Pre-Planned Trading Plan

United Therapeutics President and COO Michael Benkowitz executed pre-planned sales of common stock following option exercises on September 15, 2025.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), reported transactions on September 15, 2025, under a Rule 10b5-1 trading plan established on June 3, 2025.
• Exercised 14,625 stock options at an exercise price of $135.42 per share.
• Exercised an additional 7,875 stock options at an exercise price of $146.03 per share.
• Sold a total of 14,625 shares of common stock, acquired from the first option exercise, at weighted average prices ranging from $396.9525 to $403.0044 per share.
• Sold a total of 7,875 shares of common stock, acquired from the second option exercise, at weighted average prices ranging from $396.8657 to $403.0753 per share.
• Disposed of an additional 2,648 shares of common stock directly on the same date, without an associated option exercise.
• All common stock sales related to option exercises were executed indirectly through trusts.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a Rule 10b5-1 plan, mitigating concerns about opportunistic selling. The executive also retains significant option holdings.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-scheduled sales not based on new, non-public information, which mitigates concerns about opportunistic insider selling.
• The sale prices for the common stock were significantly higher than the option exercise prices, demonstrating a substantial profit for the reporting person.
• The reporting person retains a significant number of unexercised stock options (143,625 options at $135.42 and 41,125 options at $146.03), indicating continued alignment with shareholder interests.

Negatives

• The disposition of a total of 25,148 shares of common stock by a key executive could be perceived negatively by some investors, even if pre-planned.
• The additional direct disposition of 2,648 shares of common stock, not tied to an option exercise, represents a reduction in direct equity holdings.

Risks

• Investor perception of insider selling, even under a 10b5-1 plan, could lead to short-term negative sentiment or minor share price fluctuations.
• The reduction in the executive's direct common stock holdings, while still maintaining significant option exposure, could be interpreted as a slight decrease in immediate equity alignment.

Future Outlook

na

Industry Context

This filing details an individual executive's equity transactions and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• The transactions involved shares held indirectly by trusts where the Reporting Person is a beneficiary, and in one case, co-trustee with his spouse, having shared investment and voting power. In another case, the Reporting Person's family members are beneficiaries, and the Reporting Person has sole investment and voting power.

Stakeholder Impact

• Shareholders may observe a reduction in the President and COO's direct common stock holdings, which could be interpreted in various ways, though the pre-planned nature of the sales under a 10b5-1 plan typically reduces negative implications.
• The executive's continued significant holdings of unexercised stock options maintain a degree of alignment with long-term shareholder value.

Key Dates

Recommendation

This Form 4 reports routine, pre-planned insider transactions under a Rule 10b5-1 plan. While it involves significant share sales, the pre-scheduled nature and the executive's retained option holdings suggest these are not indicative of a change in fundamental company outlook. Therefore, this filing alone does not warrant a change in investment recommendation, and a 'hold' stance is appropriate.

Keywords

United Therapeutics, UTHR, Michael Benkowitz, Form 4, Insider Trading, Stock Options, Common Stock, 10b5-1 Plan, Executive Compensation